Angela M. Hartley Brodie, Ph.D., Is Recipient of 2012 Pharmacia-ASPET Award
For immediate release: May 23, 2012
Angela Hartley Brodie, Ph.D., professor in the Department of Pharmacology and Experimental Therapeutics at the University of Maryland School of Medicine, is the recipient of the 2012 Pharmacia-ASPET Award for Experimental Therapeutics. The Pharmacia-ASPET Award for Experimental Therapeutics is given annually to recognize and stimulate outstanding research in pharmacology and experimental therapeutics—basic laboratory or clinical research that has had a major impact on the pharmacological treatment of disease. The award is funded by an endowment from Pharmacia (now Pfizer) and by ASPET.
Dr. Brodie earned her Ph.D., in chemical pathology from the University of Manchester, United Kingdom. After receiving her Ph.D., she was awarded a fellowship from the NIH for postdoctoral training at Clark University and the Worcester Foundation for Experimental Biology in Massachusetts. She remained as a staff scientist and later became senior scientist at the Worcester Foundation. She would later join the University of Maryland as research associate professor in the Department of Pharmacology and Experimental Therapeutics in the School of Medicine. Now full professor, she also has appointments in the Department of Physiology and the University of Maryland Greenebaum Cancer Center.
Dr. Brodie's major research interests are in breast cancer treatment and the development and use of aromatase inhibitors and new treatments for prostate cancer. She is an internationally recognized scientist for her pioneering research on aromatase inhibitors for treatment of breast cancer. Her discoveries have provided hope for women who were previously unresponsive to widely accepted forms of breast cancer treatment. Her pioneering studies led to the development of aromatase inhibitors that are now approved by the FDA for treatment of breast cancer. She has expanded her research to investigate inhibitors of androgen synthesis as potential agents for treating prostate cancer.
As testimony to her major research accomplishments, she has been awarded many of the leading cancer awards including the Susan G. Komen Breast Cancer Foundation's Brinker International Award for Breast Cancer Research; the Landon Award from the American Association of Cancer Research; and the Kettering Prize from the General Motors Cancer Research Foundation. Dr. Brodie is also involved in the training of graduate students and postdoctoral fellows and teaches in medical and graduate pharmacology courses. She has served on many NIH and NCI study sections as well as being a reviewer and member of the integration panel for the U.S. Army Department of Defense Army Breast Cancer Program. She is also a member of the Advisory Board for the Komen Foundation.
Dr. Brodie will be presented with the 2012 Pharmacia-ASPET Award for Experimental Therapeutics on April 21, 2012, at the Annual Meeting of the American Society for Pharmacology and Experimental Therapeutics/Experimental Biology (EB) in San Diego, California.